The US FDA’s request that Endo Pharmaceuticals Inc. withdraw Opana ER (oxymorphone extended-release) due to its intravenous abuse potential suggests the agency will take a tougher stand on currently marketed opioids under the leadership of newly installed Commissioner Scott Gottlieb.
On June 8, FDA announced it has asked Endo to pull the long-acting opioid from the market because the drug’s...



